Risk factors associated with brain metastases in ECOG-ACRIN E1505, a phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>/=4 cm) - IIIA non-small cell lung cancer (NSCLC). Varlotto, J. M., Dahlberg, S., Wakelee, H. A., Ramalingam, S. S., Schiller, J. H. AMER SOC CLINICAL ONCOLOGY. 2017

View details for DOI 10.1200/JCO.2017.35.15_suppl.8539

View details for Web of Science ID 000411932201117